Holen Sie sich die Stockscreener-App
61.17
0.73%
-0.45
Schlusskurs vom Vortag:
$61.62
Offen:
$61.24
24-Stunden-Volumen:
554.78K
Relative Volume:
0.66
Marktkapitalisierung:
$2.84B
Einnahmen:
$1.32B
Nettoeinkommen (Verlust:
$175.44M
KGV:
16.81
EPS:
3.6395
Netto-Cashflow:
$308.08M
1W Leistung:
+3.21%
1M Leistung:
+4.42%
6M Leistung:
+20.63%
1J Leistung:
+7.00%
1-Tages-Spanne:
$60.57
$62.15
1-Wochen-Bereich:
$58.86
$62.78
52-Wochen-Spanne:
$47.31
$87.32
Haemonetics Corp Stock (HAE) Company Profile
Firmenname
Haemonetics Corp
Sektor
Branche
Telefon
(781) 848-7100
Adresse
125 SUMMER STREET, BOSTON, MA
Compare HAE vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
61.17 | 2.86B | 1.32B | 175.44M | 308.08M | 3.6395 |
ABT
Abbott Laboratories
|
96.00 | 168.22B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
338.34 | 131.49B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
85.00 | 110.66B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
60.99 | 95.46B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.44 | 46.69B | 6.07B | 1.06B | 1.34B | 1.8063 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-15 | Herabstufung | Needham | Buy → Hold |
| 2025-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-08-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-08-08 | Bestätigt | Barrington Research | Outperform |
| 2025-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-06-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-02-07 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-08 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-09-13 | Eingeleitet | CL King | Buy |
| 2024-09-11 | Eingeleitet | BofA Securities | Neutral |
| 2024-09-10 | Eingeleitet | BTIG Research | Buy |
| 2024-06-12 | Hochstufung | Needham | Hold → Buy |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2022-01-27 | Herabstufung | Needham | Buy → Hold |
| 2021-12-15 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-08-17 | Fortgesetzt | Raymond James | Outperform |
| 2021-06-17 | Eingeleitet | Citigroup | Buy |
| 2021-05-14 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2021-04-20 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2021-02-03 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2021-01-21 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-11-05 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2020-05-06 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-03-31 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2020-01-10 | Eingeleitet | Needham | Buy |
| 2019-08-07 | Bestätigt | Barrington Research | Outperform |
| 2019-05-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-05-08 | Bestätigt | Barrington Research | Outperform |
| 2018-08-09 | Bestätigt | Barrington Research | Outperform |
| 2018-02-07 | Bestätigt | Barrington Research | Outperform |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-11-08 | Bestätigt | Barrington Research | Outperform |
| 2017-08-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2017-07-13 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-02-07 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2016-11-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2016-11-07 | Bestätigt | The Benchmark Company | Hold |
| 2016-09-20 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2016-08-15 | Herabstufung | Sidoti | Buy → Neutral |
| 2016-08-02 | Bestätigt | Jefferies | Buy |
| 2016-08-02 | Bestätigt | The Benchmark Company | Hold |
Alle ansehen
Haemonetics Corp Aktie (HAE) Neueste Nachrichten
Haemonetics Corp stock (US4041191090): Why mobile-first Discover changes matter more now for medtech - AD HOC NEWS
Is Haemonetics (HAE) Using VASCADE MVP XL’s Expanded FDA Label To Deepen Its Moat? - simplywall.st
Assessing Haemonetics (HAE) Valuation After Recent Share Price Rebound And Discount To DCF Estimate - simplywall.st
Haemonetics Corp. Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
Mizuho Adjusts Haemonetics Corporation (HAE) Estimates in Sector-Wide Review - Yahoo Finance
Haemonetics Corp. Experiences Revision in Stock Evaluation Amid Market Volatility - Markets Mojo
Haemonetics Corp stock (US4041191090): Why its steady focus on blood management innovation matters m - AD HOC NEWS
A Look at Haemonetics Corp (HAE) After 3.4% Gain -- GF Value $86 - GuruFocus
HAE Maintained by Mizuho -- Price Target Lowered to $70 - GuruFocus
Haemonetics price target lowered to $84 from $88 at BTIG - TipRanks
Haemonetics price target lowered to $70 from $80 at Mizuho - TipRanks
Blood Bag Market Is Going to Boom| Haemonetics Corporation • Grifols S.A. • Macopharma - openPR.com
Q3 2026 Haemonetics Corp Earnings Call Transcript - GuruFocus
Q2 2026 Haemonetics Corp Earnings Call Transcript - GuruFocus
Haemonetics Corporation (NYSE:HAE) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Citi Maintains Haemonetics(HAE.US) With Hold Rating, Cuts Target Price to $64 - 富途牛牛
Haemonetics (HAE) Is Up 5.7% After FDA Expands VASCADE MVP XL Labeling for Larger EP Sheaths - simplywall.st
HAE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Haemonetics price target lowered to $64 from $70 at Citi - TipRanks
Is It Time To Reassess Haemonetics (HAE) After Recent Share Price Weakness? - simplywall.st
Harbor Capital Advisors Inc. Sells 22,228 Shares of Haemonetics Corporation $HAE - marketbeat.com
HAE PE Ratio & Valuation, Is HAE Overvalued - Intellectia AI
Haemonetics Corporation (HAE) Stock forecasts - Yahoo Finance UK
Haemonetics will post earnings at 6 a.m., then take questions at 8 - Stock Titan
Is It Time To Reassess Haemonetics (HAE) After Prolonged Share Price Weakness - Yahoo Finance
Allspring Global Investments Holdings LLC Sells 121,063 Shares of Haemonetics Corporation $HAE - MarketBeat
Avantis U.S. Small Cap Equity Fund's Haemonetics Corp(HAE) Holding History - GuruFocus
Automatic Blood Bag Tube Stripper Market Is Going to Boom | Terumo - openPR.com
BTIG Maintains Haemonetics(HAE.US) With Buy Rating, Maintains Target Price $88 - 富途牛牛
Haemonetics: FDA Label Expansion and New Product Launches Poised to Reignite Vascular Closure Growth by FY27 - TipRanks
Haemonetics: FDA approves expanded labeling for VASCADE MVP XL system - TipRanks
FDA Expands Approval for Haemonetics' (HAE) VASCADE MVP XL Syste - GuruFocus
Is Haemonetics (HAE) Leveraging VASCADE MVP XL’s FDA Expansion To Deepen Its EP Moat? - simplywall.st
Haemonetics wins FDA nod for expanded vascular closure system use - Investing.com
Haemonetics Wins FDA Approval to Expand Label for VASCADE MVP XL - marketscreener.com
Haemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure System - PR Newswire
Haemonetics Corp. Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
Haemonetics stock maintained at Buy by BTIG on FDA label expansion - Investing.com South Africa
Assenagon Asset Management S.A. Sells 99,083 Shares of Haemonetics Corporation $HAE - MarketBeat
Short Interest in Haemonetics Corporation (NYSE:HAE) Decreases By 29.7% - MarketBeat
Vanguard disaggregates holdings after internal realignment (NYSE: HAE) - Stock Titan
Update Recap: What drives Haemonetics Corporations stock price2026 Breakouts & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Q2 EPS Estimates for Haemonetics Boosted by Zacks Research - MarketBeat
A Look At Haemonetics (HAE) Valuation After Recent Share Price Weakness - simplywall.st
Q3 EPS Estimates for Haemonetics Increased by Zacks Research - MarketBeat
HAE Price Today: Haemonetics Corporation Stock Price, Quote & Chart - MEXC Exchange
Haemonetics Corp stock faces uncertainty amid lack of fresh catalysts in blood management sector - AD HOC NEWS
Why Haemonetics Stock Is Suddenly Bouncing Back - TipRanks
Hospital Solutions launch from Haemonetics aims to transform patient care standards - Traders Union
Haemonetics Corp Stock Surges on Strong Momentum Amid Plasma and Hemostasis Demand - AD HOC NEWS
Don't Get Too Worked Up Over Haemonetics's Earnings - Yahoo
Finanzdaten der Haemonetics Corp-Aktie (HAE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):